EUCTR2011-002781-21-GBActive, not recruitingPhase 1
A clinical study to evaluate the biological effects of administering rimantadine in patients with hepatitis C virus (HCV) infection alongside standard combination therapy with pegylated interferon and ribavirin. - Hepatitis C Rimantadine + Antiviral Combination Therapy -HepRiACT v2.0
eeds Teaching Hospitals0 sites22 target enrollmentStarted: January 12, 2012Last updated:
Drugs
Trial Snapshot
- Phase
- Phase 1
- Status
- Active, not recruiting
- Sponsor
- Enrollment
- 22
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional clinical trial of medicinal product
Eligibility Criteria
Inclusion Criteria
- •Each patient MUST: • Have a diagnosis of HCV infection, genotype 1 • Be eligible for standard combination therapy with pegylated IFN and ribavirin • Be at least 18 but no more than 65 years of age • Have signed an informed consent indicating that the patient is aware of the infectious nature of their disease and have been informed of the procedures of the protocol, the experimental nature of the therapy, alternatives, potential benefits, side effects, risks, and discomforts • Be willing and able to comply with scheduled visits, the treatment plan, and laboratory tests • Have no contraindications to receiving rimantadine therapy
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 22
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range 0
Exclusion Criteria
- •No patient may: • Have dementia or altered mental status that would prohibit informed consent. • Have any condition which would deem the patient ineligible for combination therapy with pegylated IFN or ribavirin. This includes pregnancy, significant cardiac, renal or autoimmune disease, severe depression or psychosis, and previous organ transplantation • Any condition which would preclude the use of rimantadine. This comprises cirrhosis or liver failure (specific criteria for diagnosis are detailed in the research protocol), significant renal impairment, pregnancy, epilepsy or history of unexplained seizures • Have any other severe, acute, or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or study drug administration or may interfere with the interpretation of study results and, in the judgment of the Chief Investigator, would make the patient inappropriate for this study. This includes the presence of end stage liver disease (i.e. cirrhosis).
Investigators
Similar Trials
Active, not recruiting
Phase 1
The evaluation of safety and biological effects of cancer-killing virus vaccine given to patients with advanced brain tumoursMalignant neoplasm of brain, high-grade brain tumourMalignant neoplasm of brainCancerISRCTN51762486niversity of Leeds12
Recruiting
Phase 1
Clinical study on Evaluation of therapeutic effect of acupuncture on cervical spondylosis by shear wave ultrasonic elastographyCervical spondylopathyITMCTR2100004262Sichuan Academy of Medical Sciences, Sichuan Provincial People's Hospital
Recruiting
Not Applicable
Effect of trutyadi churna in amavata with special reference to rheumatoid arthritis.CTRI/2021/08/035463DR VISHNUPRIYA SEETHARAM
Not yet recruiting
Phase 3
Ayurvedic medicine-siddartakadi yoga in depressioCTRI/2024/04/065341I
Recruiting
Phase 1
The experimental study and clinical effect evaluation of multimodal ultrasound for plantar fasciitisplantar fasciitisITMCTR2022000056Guang'anmen Hospital China Academy of Chinese Medical Science